Equipred
Active substance
ATC code
Species
Horses
Indications
Alleviation of inflammatory and clinical parameters associated with recurrent airway obstruction (RAO – severe asthma) in horses, in combination with environmental control.
Dose to be administered and administration route
For oral use.
The product should be mixed in small amount of feed.
To ensure administration of the correct dose, body weight should be determined as accurately as
possible to avoid under- or overdosing. Tablets may be divided along score lines to facilitate accurate dosing.
A single dose of 1 mg prednisolone/kg body weight per day corresponding to 2 tablets per 100 kg body weight.
Treatment may be repeated at 24 hour intervals during 10 consecutive days.
Adverse reactions
Very rarely, laminitis has been observed after use of the product. Therefore, horses should be
monitored frequently during the treatment period.
Very rarely, neurological signs such as ataxia, recumbency, head tilting, restlessness or incoordination have been observed after use of the product.
The significant dose related cortisol suppression very commonly noticed during therapy is a result of effective doses suppressing the hypothalamic-pituitaryadrenal axis. Following cessation of treatment, signs of adrenal insufficiency extending to adrenocortical atrophy can arise and this may render the animal unable to deal adequately with stressful situations.
The significant increase in triglycerides occurs very commonly. This may result in a significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g. redistribution of body fat, increase in body weight, muscle weakness and wastage and osteoporosis.
The increase of alkaline phosphatase by glucocorticoids is very rarely observed and could be related to enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.
Gastrointestinal ulceration has been very rarely reported and gastrointestinal ulceration may be exacerbated by steroids in animals given non-steroidal anti-inflammatory drugs.
Other gastrointestinal symptoms that have been very rarely observed are colic and anorexia.
Excessive sweating has been very rarely observed. Very rarely urticaria has been observed.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
